Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedChronic neutrophilic leukemia: a clinical perspectiveJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsAn International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?JAK2 inhibitors for myeloproliferative neoplasms: what is next?Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.Genomics of chronic neutrophilic leukemia.Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinibRuxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AMLRecent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.Atypical chronic myeloid leukemia: a rare entity with management challenges.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.Chronic neutrophilic leukemia: new science and new diagnostic criteria.Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic/myeloproliferative neoplasm.
P2860
Q26738514-B36C4788-E931-46CD-A6B4-7FFD715E3290Q26781167-867D08B5-25A5-46AD-B154-20C8CE87E989Q26782539-18970A6B-6415-4561-B24D-4BF6385BEDFBQ36708989-D3086856-F811-452A-83D3-4D1F5C71954FQ37349392-1343F610-9897-4FBE-972F-0EF88C43EEE8Q38292400-A12F906B-42B4-4785-A137-F1C60F5A4045Q38684435-669C7E56-C2C0-4E9C-B09A-8253098251B5Q38993081-41DE0E63-038A-4CE2-98F0-4734102D7BB6Q39059515-BD22E483-AB39-4F96-9488-28E2B42A2641Q42336327-292F0082-335F-43B1-88EA-2FD24C16F815Q42344556-3D337878-A291-472F-9192-67910D914D61Q42664472-2DFA9882-12EC-4E79-87A4-57679776E63BQ42695278-B6A7D0A5-2F38-4DCF-84B1-C0CC8A8AAB08Q47140442-0D53A1A2-2A2A-468E-967D-D48DA230729FQ47789741-701F2D42-46FD-4302-A640-71BC658D1FB2Q48109284-15D3A76B-7591-44D2-889C-8B52B9382BAAQ49239291-B50F9E9E-F583-4B52-9ACB-911FFE29DE55Q49887981-C6C19297-9996-4303-8A83-56852D5F2617Q54303081-A2825546-0810-4B9B-AC58-4F1681207433Q54964443-8304F2F1-FB28-41FD-91DA-9EC75AC1C472
P2860
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Significant clinical response ...... ical chronic myeloid leukemia.
@ast
Significant clinical response ...... ical chronic myeloid leukemia.
@en
type
label
Significant clinical response ...... ical chronic myeloid leukemia.
@ast
Significant clinical response ...... ical chronic myeloid leukemia.
@en
prefLabel
Significant clinical response ...... ical chronic myeloid leukemia.
@ast
Significant clinical response ...... ical chronic myeloid leukemia.
@en
P2093
P2860
P921
P1476
Significant clinical response ...... ical chronic myeloid leukemia.
@en
P2093
Elliott F Winton
Jeffrey W Tyner
Julia E Maxson
Kim-Hien T Dao
Magdolna B Solti
P2860
P356
10.1016/J.LRR.2014.07.002
P577
2014-08-01T00:00:00Z